Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biotech Deals Stand Out In 2018 Korean Licensing Trends

Executive Summary

Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.


Related Content

Roivant Buoys Anti-Infective Portfolio With Novel iNtRON Asset
Kolon Bounces Back From Failed Japan Invossa Deal With Bigger Mundipharma Alliance
Yuhan Strikes Long-Awaited Lung Cancer Deal Through Huge Janssen Alliance
Deal Watch: Emergent Strikes Again, Acquiring Adapt And Its Opioid Overdose Drug For $635m
Yuhan Licenses Out Degenerative Disc Therapy To Spine Despite Earlier Trial Failure
Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
Oncology, Diabetes Dominate Korean Out-Licensing But Deals And Value Decline
Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar
Deal Watch: Roche Goes All-In On Real-World Data With Flatiron Acquisition
Dong-A Ties With NeuroBo For Diabetic Neuropathy, Alzheimer's


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts